Status and development of the tumor microenvironment in hepatocellular carcinoma

Progress in Biochemistry and Biophysics

Volumn 39, Issue 5, 2012, Pages 416-422

  Liu, Zhi Lei ^a,b   Sun, Wei ^a,b   He, Fu Chu ^b   Cong, Xian Ling ^c   Jiang, Ying ^a,b  

^a Anhui Medicial University Graduate Department   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c JUIN UNIVERSITY   (China)

Author keywords

Hepatocellucar carcinoma; Tissue interstitial fluid (TIF); Tumor microenvironment

Indexed keywords

EID: 84865044419     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2011.00383     Document Type: Review

References (71)

1. Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2):74-108 (Pubitemid 40372904)
2. Yang J D, Roberts L R. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol, 2010, 7(8): 448-458
3. Fidler I J. The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer, 2003, 3(6): 453-458 (Pubitemid 37328849)
4. Bissell M J, Hines W C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med, 2011, 17(3): 320-329
5. Sogn J A, Anton-Culver H, Singer D S. Meeting report: NCI think tanks in cancer biology. Cancer Res, 2005, 65(20): 9117-9120 (Pubitemid 41507969)
6. Mbeunkui F, Johann D J, Jr. Cancer and the tumor microenvironment: A review of an essential relationship. Cancer Chemother Pharmacol, 2009, 63(4): 571-582
7. Liotta L A, Kohn E C. The microenvironment of the tumour-host interface. Nature, 2001, 411(6835): 375-379
8. Joyce J A, Pollard J W. Microenvironmental regulation of metastasis. Nat Rev Cancer, 2009, 9(4): 239-252
9. Hede K. Environmental protection: studies highlight importance of tumor microenvironment. J Natl Cancer Inst, 2004, 96(15): 1120-1121 (Pubitemid 39207040)
10. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer, 2006, 6(5): 392-40
11. Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci, 2010, 15: 166-179
12. Overall C M, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer, 2006, 6(3): 227-239 (Pubitemid 43292566)
13. Coussens L M, Werb Z. Inflammation and cancer. Nature, 2002, 420(6917): 860-867 (Pubitemid 36019639)
14. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res, 2010, 316(8): 1324-1331
15. Neaud V, Faouzi S, Guirouilh J, et al. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology, 1997, 26(6): 1458-1466 (Pubitemid 27520010)
16. Fransvea E, Mazzocca A, Antonaci S, et al. Targeting transforming growth factor (TGF)-betaRI inhibits activation of betal integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology, 2009, 49(3): 839-850
17. Friedman S L, Roll F J, Boyles J, et al. Hepatic lipocytes: The principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA, 1985, 82(24): 8681-8685 (Pubitemid 16101107)
18. Wynn T A. Cellular and molecular mechanisms of fibrosis. J Pathol, 2008, 214(2): 199-210 (Pubitemid 351160157)
19. Krizhanovsky V, Yon M, Dickins R A, et al. Senescence of activated stellate cells limits liver fibrosis. Cell, 2008, 134(4): 657-667
20. Friedman S L. Liver fibrosis-from bench to bedside. J Hepatol, 2003, 38(Suppl 1):S38-53
21. Sokolovic A, Sokolovic M, Boers W, et al. Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells. Fibrogenesis Tissue Repair, 2010, 3: 3
22. Dubuisson L, Lepreux S, Bioulac-Sage P, et al. Expression and cellular localization of fibrillin-1 in normal and pathological human liver. J Hepatol, 2001, 34(4): 514-522 (Pubitemid 32328507)
23. Faouzi S, Lepreux S, Bedin C, et al. Activation of cultured rat hepatic stellate cells by tumoral hepatocytes. Lab Invest, 1999, 79(4): 485-493 (Pubitemid 29190438)
24. Amann T, Bataille F, Spruss T, et al. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci, 2009, 100(4): 646-653
25. Chew V, Tow C, Teo M, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol, 2010, 52(3): 370-379
26. Shen X, Li N, Li H, et al. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. J Cancer Res Clin Oncol, 2010, 136(11): 1745-1754
27. Li L, Li S P, Min J, et al. Hepatoma cells inhibit the differentiation and maturation of dendritic cells and increase the production of regulatory T cells. Immunol Lett, 2007, 114(1): 38-45 (Pubitemid 47625596)
28. Roberts R A, Ganey P E, Ju C, et al. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci, 2007, 96(1): 2-15 (Pubitemid 46323203)
29. Karck U, Peters T, Decker K. The release of tumor necrosis factor from endotoxin-stimulated rat Kupffer cells is regulated by prostaglandin E2 and dexamethasone. J Hepatol, 1988, 7(3): 352-361 (Pubitemid 19000525)
30. Lysz T W, Billiar T R, Curran R D, et al. Kupffer cell-hepatocyte interactions and the changes in 1-14C-arachidonate incorporation in response to endotoxin in vitro. Prostaglandins, 1990, 39(5): 497-514 (Pubitemid 20150763)
31. Benetti A, Berenzi A, Gambarotti M, et al. Transforming growth factor-beta 1 and CD 105 promote the migration of hepatocellular carcinoma-derived endothelium. Cancer Res, 2008, 68(20): 8626-8634
32. Zhang T, Sun H C, Xu Y, et al. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res, 2005, 11(24 Pt 1): 8557-8563 (Pubitemid 43005900)
33. =[33] Oseini A M, Roberts L R. PDGFRalpha: A new therapeutic target in the treatment of hepatocellular carcinoma?. Expert Opin Ther Targets, 2009, 13(4): 443-454
34. Thiery J P, Acloque H, Huang R Y, et al. Epithelial-mesenchymal transitions in development and disease. Cell, 2009, 139(5): 871-890
35. Nitta T, Kim J S, Mohuczy D, et al. Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology, 2008, 48(3): 909-919
36. Zeisberg M, Bottiglio C, Kumar N, et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol, 2003, 285(6): F1060-1067 (Pubitemid 37421041)
37. Yang J D, Nakamura I, Roberts L R. The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. Semin Cancer Biol, 2011, 21(1): 35-43
38. Ji J, Zhao L, Budhu A, et al. Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol, 2010, 52(5): 690-697
39. Liu C J, Lee P H, Lin D Y, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase D trial for safety and optimal dosage. J Hepatol, 2009, 50(5): 958-968
40. Giannelli G, Fransvea E, Bergamini C, et al. Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin Cancer Res, 2003, 9(10 Pt 1): 3684-3691 (Pubitemid 37169236)
41. Mizuno H, Ogura M, Saito Y, et al. Changes in adhesive and migratory characteristics of hepatocellular carcinoma (HCC) cells induced by expression of alpha3betal integrin. Biochim Biophys Acta, 2008, 1780(3): 564-570 (Pubitemid 351381248)
42. Wu Y, Zuo J, Ji G, et al. Proapoptotic function of integrin beta(3) in human hepatocellular carcinoma cells. Clin Cancer Res, 2009, 15(1): 60-69
43. Song J D, Yang Y, Li F. Medical Cell Biology (3th edition). Beijing: People Health Press, 2004: 88-92
44. Wiig H, Tenstad O, Iversen P O, et al. Interstitial fluid: The overlooked component of the tumor microenvironment?. Fibrogenesis Tissue Repair, 2010, 3: 12
45. Celis J E, Gromov P, Cabezon T, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: A novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics, 2004, 3(4): 327-344 (Pubitemid 38702087)
46. Sun W, Ma J, Wu S, et al. Characterization of the liver tissue interstitial fluid (TIF) proteome indicates potential for application in liver disease biomarker discovery. J Proteome Res, 2010, 9(2): 1020-1031
47. Teng P N, Bateman N W, Hood B L, et al. Advances in proximal fluid proteomics for disease biomarker discovery. J Proteome Res, 2010, 9(12): 6091-6100
48. Bacon A L, Farrington S M, Dunlop M G. Mutation frequency in coding and non-coding repeat sequences in mismatch repair deficient cells derived from normal human tissue. Oncogene, 2001, 20(51): 7464-7471 (Pubitemid 33086905)
49. Ikushima H, Miyazono K. TGFbeta signalling: A complex web in cancer progression. Nat Rev Cancer, 2010, 10(6): 415-424
50. van Zijl F, Mair M, Csiszar A, et al. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene, 2009, 28(45): 4022-4033
51. Yang L, Pang Y, Moses H L. TGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol, 2010, 31(6): 220-227
52. Bangoura G, Liu Z S, Qian Q, et al. Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. World J Gastroenterol, 2007, 13(23): 3176-3182 (Pubitemid 47064579)
53. Poon R T, Ho J W, Tong C S, et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg, 2004, 91(10): 1354-1360 (Pubitemid 39331462)
54. El-Assal O N, Yamanoi A, Soda Y, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver. Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology, 1998, 27(6): 1554-1562 (Pubitemid 28264678)
55. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell, 2010, 141(1): 52-67
56. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol, 2000, 2(10): 737-744
57. Chen J S, Wang Q, Fu X H, et al. Involvement of P13K/PTEN/ AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res, 2009, 39(2): 177-186
58. Masson V, de la Ballina L R, Munaut C, et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J, 2005, 19(2): 234-236 (Pubitemid 40189266)
59. Sato T, Asanuma Y, Masaki Y, el id. Changes in tumor necrosis factor-a and interleukin-1 beta production following liver surgery on cirrhotic patients. Hepatogastroenterology, 1996, 43(11): 1148-1153 (Pubitemid 26358506)
60. Ikeguchi M, Hirooka Y. Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas. Onkologie, 2005, 28(5): 255-259 (Pubitemid 40754671)
61. Budhu A, Wang X W. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol, 2006, 80(6): 1197-1213 (Pubitemid 44904957)
62. Zhang J P, Yan J, Xu J, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol, 2009, 50(5): 980-989
63. Kaplan R N, Riba R D, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 2005, 438(7069): 820-827 (Pubitemid 41753060)
64. Kaplan R N, Psaila B, Lyden D. Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev, 2006, 25(4): 521-529 (Pubitemid 46071861)
65. Qi F F, He F C, Jiang Y. Prog Biochem Biophys, 2009, 36(10): 1244-1251
66. Budhu A, Forgues M, Ye Q H, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell, 2006, 10(2): 99-111 (Pubitemid 44202603)
67. Zheng X N, Lin Z, Liu Y. Chin J Oncology, 1998, 20(1): 15-17
68. Albini A, Sporn M B. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer, 2007, 7(2): 139-147 (Pubitemid 46160989)
69. Antonaci S, Giannelli G. Rationale for new drugs targeting the tissue microenvironment in patients with HCC. Curr Pharm Des, 2007, 13(32): 3288-3291 (Pubitemid 350201683)
70. Liu T, Lin B, Qin J. Carcinoma-associated fibroblasts promoted tumor spheroid invasion on a microfluidic 3D co-culture device. Lab Chip, 2010,10(13): 1671-1677
71. Fischbach C, Chen R, Matsumoto T, et al. Engineering tumors with 3D scaffolds. Nat Methods, 2007, 4(10): 855-860 (Pubitemid 350055585)